Correct consolidated financial reports from 2023Q1 to Q4, independent 2024Q4 financial report, and iXBRL, which have no impact on income and losses and net assets.

1.Date of occurrence of the event:2024/05/10 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios: N/A 5.Cause of occurrence: Pursuant to letter No. 11300023721 from Taipei Exchange, the Company’s Board resolved to correct financial reports for 2023 each quarter. 6.Information items/ statements to be corrected: […]